Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14620925 | 0.89 | ALDH1A1 (0.44) | KCNH2HPGDMAPTALDH1A1CYP1A2 | |
| SCHEMBL8149163 | 0.83 | MAPT (0.46) | HPGDMAPTALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL15778741 | 0.82 | GAA (0.47) | KCNH2HPGDMAPTALDH1A1CYP1A2 | |
| SCHEMBL13119736 | 0.82 | HPGD (0.46) | KCNH2HPGDCYP2C9CYP3A4PTGDR2 | |
| SCHEMBL3611237 | 0.82 | KCNH2 (0.45) | KCNH2HPGDMAPTCYP2C9CYP3A4 | |
| SCHEMBL13119733 | 0.78 | KCNH2 (0.43) | KCNH2HPGDMAPTCYP2C9CYP2C19 | |
| SCHEMBL3372818 | 0.76 | MAPT (0.62) | HPGDMAPTALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL16661979 | 0.76 | SMN1; SMN2 (0.54) | — | |
| SCHEMBL508238 | 0.75 | KCNH2 (0.39) | KCNH2MAPTALDH1A1CYP3A4GPR35 | |
| SCHEMBL12128097 | 0.74 | KCNH2 (0.43) | KCNH2MAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663490-B2 | Process for making reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9598397-B2 | Process for making reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160297794-A1 | PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20150329521-A1 | PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297794-A1 | PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, TYMS | KCNH2 4562/4885HPGD 805/4885MAPT 1977/4885 |
| US-20150329521-A1 | PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, TYMS | KCNH2 4548/4885HPGD 785/4885MAPT 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.